Please login to the form below

ID Search & Selection

ID Search & Selection is a specialist recruitment agency working across the healthcare / medical communications sector. We are a trusted partner to pharmaceutical companies and medical communications agencies and recruit at all levels of seniority for both permanent and contract/freelance jobs.Our process is highly consultative; we take time to understand a client's requirements and only present candidates that fit the brief.

This is a FREE listing




Below are full profiles from other companies in this area

Syneos Health®

Syneos Health® (Nasdaq:SYNH) is the only fully integrated biopharmaceutical solutions organization. The Company, including a Contract Research Organization (CRO) and Contract Commercial Organization (CCO), is purpose-built to accelerate customer performance to address modern market realities. Learn more about how we are Shortening the distance from lab to life® at syneoshealth.com.

View profile

Company Details

ID Search & Selection

Telephone:+44 (0)1932 797996

Contact

Address:
32 Station Approach
West Byfleet
Surrey
KT14 6NF
United Kingdom

Latest content from PMHub

Patient recruitment and retention 2021 state of play
At COUCH Health, we’ve recently done some social listening to look into the discussions around ‘patient recruitment’ and ‘patient retention’, to see if these conversations have been impacted by the COVID-19 pandemic. Let’s take a closer look at our findings…
COUCH Health
Live Webinar: Women in Leadership: Barriers & Opportunities in the Life Science Industry
Fireside Chat with  Allison Gaw, Executive Director, Corporate and Business Development at Chinook Therapeutics Impetus Digital
The UK has approved the first vaccine for COVID-19. What now?
The authorisation of Pfizer/BioNtech's mRNA vaccine by the MHRA is great news, but no-one has ever tried to roll out a vaccine as rapidly as this one, so we have some challenges to overcome.
Langland
Clinical trials and the diversity principle
If they were ever really hidden, 2020 revealed the expensive-sounding problems limiting diversity in clinical trials. Solutions are overdue.
Langland